// App-Quantinova.ai

CTNI-03 : A PHASE I/IIA, OPEN-LABEL STUDY OF THE BRAIN-PENETRANT PARP1-SELECTIVE INHIBITOR AZD9574 AS MONOTHERAPY AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES (CERTIS1)

Researchers

Presenter

  • Nancy Mueller

Principal Investigators

  • Stephen Luen

  • Roger Stupp

  • Anthony Chalmers

  • Baisong Huang

  • Massimo Squatrito

  • Barry Davies

  • Petra Hamerlik

  • Timothy Yap

Medical Centers

  • University of Texas, MD Anderson Cancer Center, Houston, TX, USA

  • Northwestern University — Neurological Surgery

  • AstraZeneca, Gaithersburg, MD, USA

  • AstraZeneca, Waltham, MA, USA

  • AstraZeneca, Saffron Walden, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • Feinberg School of Medicine, Chicago, IL, USA

  • PETER MACCALLUM CANCER CENTRE, MELBOURNE, Australia.

Locations

  • United States

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Gliomas

Biomarkers

  • N/A

Drug/Treatment

  • ribose

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • First-In-Human

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved